Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;303(2):285-311.
doi: 10.1007/s00404-020-05865-z. Epub 2020 Nov 21.

The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials

Chongzhen Guo  1   2 , Chengda Yan  1   2 , Lianyue Qu  1   2 , Rongrong Du  1   2 , Jianyang Lin  3   4
Affiliations
Review

The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials

Chongzhen Guo et al. Arch Gynecol Obstet. 2021 Feb.

Abstract

Purpose: To evaluate the efficacy and toxicity of angiogenesis inhibitors for the treatment of ovarian cancer patients, we conducted a meta-analysis of the published literature on this subject.

Methods: In this meta-analysis, we searched PubMed, EMBASE, Web of Science, and Cochrane Library databases for randomized controlled trials (RCTs). The literature search was performed up to August 12, 2019. The risk of bias of the included studies was evaluated using The Cochrane Collaboration's tool, and the statistical analyses were performed using RevMan 5.3 software. The sensitivity analysis was performed with Stata 12.0 software.

Results: 22 RCTs with 11,254 patients were included. Our meta-analysis demonstrates that angiogenesis inhibitors therapy can significantly improve progression-free survival (PFS) (hazard ratio [HR] 0.71, 95% CI 0.63-0.79, I2 = 80%, P < 0.00001) and overall survival (OS) (HR 0.95, 95% CI 0.90-0.99, I2 = 0%, P = 0.03) in ovarian cancer patients. The subgroups results suggest differences in the benefit in OS in first-line treatment (HR 1.00, 95% CI 0.93-1.08, I2 = 0%, P = 0.90) compared with treatment at relapse (HR 0.87, 95% CI 0.81-0.95, I2 = 0%, P = 0.0008). The PFS improved both in first-line treatment (HR 0.87, 95% CI 0.79-0.95, I2 = 60%, P = 0.003) and recurrent treatment (HR 0.60, 95% CI 0.53-0.67, I2 = 57% P < 0.0001) patients. The PFS and OS in recurrent group were prolonged both in the platinum-resistant group(PFS: HR 0.50, 95% CI 0.42-0.60, I2 = 0%, P < 0.00001; OS: HR 0.76, 95% CI 0.62-0.93, I2 = 0%, P = 0.007) and the platinum-sensitive group (PFS: HR 0.58, 95% CI 0.49-0.69, I2 = 64%, P < 0.00001; OS: HR 0.88, 95% CI 0.79-0.99, I2 = 0%, P = 0.03). However, this therapy is associated with a higher risk of common adverse events of grade ≥ 3 (risk ratio [RR]: 1.12; 95% CI 1.07-1.17; I2 = 0%, P = 0.68) such as arterial thromboembolic disease, ascites, diarrhea, gastrointestinal perforations, headache, hemorrhagic, hypertension, hypokalemia, leucopenia, pain, proteinuria, thrombocytopenia, and thrombosis or embolism.

Conclusion: This meta-analysis suggests angiogenesis inhibitors may significantly improve PFS and OS of ovarian cancer patients and increase the incidence of common adverse events.

Keywords: Angiogenesis inhibitors; Ovarian cancer; Overall survival; Progression-free survival; Toxicity.

PubMed Disclaimer

References

    1. Siegel Rebecca L, Miller Kimberly D (2020) Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590 - DOI - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492 - DOI - PubMed - PMC
    1. Luvero D, Milani A, Ledermann JA (2014) Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol 6(5):229–239. https://doi.org/10.1177/1758834014544121 - DOI - PubMed - PMC
    1. Jászai J, Schmidt MHH (2019) Trends and challenges in tumor anti-angiogenic therapies. Cells 8(9):1102. https://doi.org/10.3390/cells8091102 - DOI - PMC
    1. Abdalla AME, Xiao L, Ullah MW, Yu M, Ouyang C, Yang G (2018) Current challenges of cancer anti-angiogenic therapy and the promise of nanotherapeutics. Theranostics 8(2):533–548. https://doi.org/10.7150/thno.21674 - DOI - PubMed - PMC

MeSH terms

Substances

LinkOut - more resources